Key result
The 22q11.2 microdeletion is linked to a ~30% rate of developing schizophrenia.
Why the study?
22q11.2 deletion syndrome is a significant genetic risk factor for schizophrenia, providing a homogeneous population to study the disease's pathobiology.
The 22q11.2 microdeletion is a major genetic risk factor for schizophrenia, offering a unique opportunity to study the disease's pathobiology through both clinical populations and animal models.
May inform genetic counseling for 22q11DS families; leaves open translation to routine schizophrenia screening.
Over the last fifteen years it has become established that 22q11.2 deletion syndrome (22q11DS) is a true genetic risk factor for schizophrenia. Carriers of deletions in chromosome 22q11.2 develop schizophrenia at rate of 25-30% and such deletions account for as many as 1-2% of cases of sporadic schizophrenia in the general population. Access to a relatively homogeneous population of individuals that suffer from schizophrenia as the result of a shared etiological factor and the potential to generate etiologically valid mouse models provides an immense opportunity to better understand the pathobiology of this disease. In this review we survey the clinical literature associated with the 22q11.2 microdeletions with a focus on neuroanatomical changes. Then, we highlight results from work modeling this structural mutation in animals. The key biological pathways disrupted by the mutation are discussed and how these changes impact the structure and function of neural circuits is described.
No takes yet. Share an insight, caveat, or question.
Drew et al. (2010) conducted a review in 22q11.2 deletion syndrome and schizophrenia. 22q11.2 microdeletion was evaluated. Carriers of the 22q11.2 microdeletion develop schizophrenia at a rate of 25-30%, accounting for 1-2% of sporadic schizophrenia cases in the general population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: